Nocturia Global Market Report 2025

The nocturia market size has grown strongly in recent years. It will grow from $2.87 billion in 2024 to $3.11 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth during the historic period can be attributed to the increasing prevalence of cardiovascular diseases, a rising incidence of insomnia, an aging population, greater awareness of nocturia and related conditions, and a rise in comorbidities.

The nocturia market size is expected to see strong growth in the next few years. It will grow to $4.23 billion in 2029 at a compound annual growth rate (CAGR) of 8%. The growth during the forecast period can be attributed to the increasing prevalence of bladder obstruction disorders and urinary tract inflammation, a rising incidence of nocturia due to various risk factors, high fluid intake contributing to nocturia, growing awareness of its connection to sleep disorders and kidney health, and the expanding aging population. Key trends in the forecast period include advancements in diagnostics, the development of new drugs, increased research and investment in nocturia treatments, progress in both surgical and non-surgical treatment options, and the adoption of personalized medicine.

The increasing prevalence of cardiovascular diseases is expected to drive the expansion of the nocturia market. Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels, including heart disease, stroke, and hypertension. Several factors contribute to the growing incidence of cardiovascular diseases, such as aging populations, sedentary lifestyles, unhealthy diets, smoking, excessive alcohol consumption, obesity, high blood pressure, high cholesterol, diabetes, and genetic predisposition. Nocturia is a common symptom among patients with cardiovascular diseases, leading to increased demand for diagnostic and treatment solutions. As cardiovascular conditions continue to rise globally due to aging and unhealthy lifestyles, the need for effective nocturia management will expand. For example, in May 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that heart disease was responsible for 702,880 deaths in the United States in 2022, accounting for 20% of all fatalities. Each year, approximately 805,000 individuals suffer a heart attack, with 605,000 being first-time cases and 200,000 occurring in those with a prior history. Consequently, the rising prevalence of cardiovascular diseases is fueling the growth of the nocturia market.

Leading companies in the nocturia market are focusing on developing innovative treatments, such as orally disintegrating tablets, to improve patient convenience and compliance. Orally disintegrating tablets (ODTs) are solid dosage forms that dissolve rapidly in the mouth without requiring water, making them particularly beneficial for patients who have difficulty swallowing. For instance, in July 2024, Adalvo Limited, a Malta-based pharmaceutical company, launched Desmopressin ODT in Europe to treat conditions that cause excessive fluid loss, such as central cranial diabetes insipidus. This synthetic vasopressin tablet helps manage diabetes insipidus, excessive thirst and urination, and bedwetting by mimicking the natural hormone and reducing water excretion in urine. Additionally, it is used to treat mild to moderate hemophilia A and von Willebrand disease by promoting the release of blood clotting factors.

In March 2022, Acerus Pharmaceuticals Corporation, a Canada-based biopharmaceutical company, acquired Serenity Pharmaceuticals LLC for an undisclosed amount. This acquisition granted Acerus Pharmaceuticals global rights to Noctiva, strengthening its portfolio in urology and men’s health. The deal positions the company for accelerated growth and improved long-term performance. Serenity Pharmaceuticals LLC, a US-based pharmaceutical company, specializes in developing therapies for voiding disorders and urinary health conditions, including nocturia.

Major players in the nocturia market are Pfizer Inc, Merck & Co. Inc, AbbVie Inc, Sanofi S.A, GlaxoSmithKline plc, Viatris Inc, Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd, Astellas Pharma Inc, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd, Ferring Pharmaceuticals A/S, Avadel Pharmaceuticals plc, UroGen Pharma Ltd, Sanwa Kagaku Co. Ltd., Urovant Sciences Inc, Serenity Pharmaceuticals LLC, Vantia Therapeutics Inc, AA Pharma Inc, Wellesley Pharmaceuticals Inc.

North America was the largest region in the nocturia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in nocturia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nocturia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Nocturia is a medical condition characterized by the need to wake up at night one or more times to urinate. It is classified as a lower urinary tract symptom (LUTS) and can stem from various underlying causes, such as excessive fluid intake before bedtime, overactive bladder, urinary tract infections, diabetes, or prostate enlargement in men. Nocturia can significantly affect sleep quality and overall health, leading to fatigue and reduced daytime productivity.

The primary drugs used for nocturia treatment include anticholinergic drugs, desmopressin, antibiotics, antispasmodics, and other medications. Anticholinergic drugs work by blocking acetylcholine to reduce involuntary bladder contractions, helping to manage overactive bladder and nocturia. These medications are indicated for conditions such as mixed nocturia, low nocturnal bladder capacity, nocturnal polyuria, and global polyuria. Nocturia can be caused by factors such as urological infections, bladder tumors, diuretic medications, alcohol or caffeine consumption, liver infections, diabetes, and pregnancy. These treatments are utilized by various end users, including hospitals, home care settings, and clinics.

The nocturia market research report is one of a series of new reports that provides nocturia market statistics, including the nocturia industry global market size, regional shares, competitors with the nocturia market share, detailed nocturia market segments, market trends, and opportunities, and any further data you may need to thrive in the nocturia industry. This nocturia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nocturia market consists of revenues earned by entities by providing services such as diagnostic services, pharmacological treatment services, behavioral therapy and lifestyle modification services and telemedicine and remote consultation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The nocturia market also includes sales of bladder control devices, alpha-blockers, diuretics, and tricyclic antidepressants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.